Defiance Autism Impact ETF (ASD)
| Assets | $1.39M |
| Expense Ratio | 0.79% |
| PE Ratio | 19.55 |
| Forward PE | 15.79 |
| Shares Out | 50,000 |
| Dividend | $0.01 (0.03%) |
| Ex-Dividend Date | Sep 23, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | 0.56% |
| Volume | 65 |
| Open | 27.63 |
| Previous Close | 27.51 |
| Day's Range | 27.63 - 27.63 |
| 52-Week Low | 24.59 |
| 52-Week High | 28.52 |
| Beta | n/a |
| Holdings | 41 |
| Inception Date | Jun 1, 2026 |
About ASD
Fund Home PageThe Defiance Autism Impact ETF (ASD) is an exchange-traded fund that is based on the VettaFi Autism Impact index. The fund tracks an equal-weighted index of companies from developed markets supporting individuals on the autism spectrum and broader community. The fund donates profits to organizations focused on autism care, research, and access to resources. ASD was launched on Jun 1, 2026 and is issued by Defiance.
Top 10 Holdings
32.54% of assets| Name | Symbol | Weight |
|---|---|---|
| Acadia Healthcare Company, Inc. | ACHC | 3.51% |
| Revvity, Inc. | RVTY | 3.43% |
| H. Lundbeck A/S | HLBBF | 3.35% |
| Eli Lilly and Company | LLY | 3.32% |
| BrightSpring Health Services, Inc. | BTSG | 3.27% |
| Sumitomo Pharma Co., Ltd. | 4506 | 3.23% |
| Teva Pharmaceutical Industries Limited | TEVA | 3.17% |
| Takeda Pharmaceutical Company Limited | 4502 | 3.11% |
| Novartis AG | NOVN | 3.09% |
| Roche Holding AG | ROP | 3.05% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 23, 2026 | $0.00199 | Sep 24, 2026 |
| Jun 24, 2026 | $0.00597 | Jun 25, 2026 |
Performance
News
Defiance CEO on Motivation Behind First Autism ETF
Matthew Bielski, founder and CEO of Defiance ETFs, recently joined Scarlet Fu and Eric Balchunas on Bloomberg's ETF IQ to discuss the Defiance Autism Impact ETF (ASD) and the personal family experienc...
What Advisors Need to Know About the First Autism ETF
As autism diagnoses rise, and research, regulation, and public awareness reshape the landscape, a broader neurodiversity care ecosystem is taking shape.
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
SAN FRANCISCO and BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering ...
Defiance Launches the First Autism-Impact ETF (Ticker: ASD), Donating Profits to Autism Causes *
MIAMI, June 02, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs today announced the launch of the Defiance Autism Impact ETF (Ticker: ASD) , the first exchange-traded fund designed to provide targeted exposure...